Predictors of Early Mortality in Acute Myeloid Leukemia: A Population Based Analysis Using SEER Data
Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · 377-387
DOI: 10.1016/j.clml.2026.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Shahzaib Maqbool und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, HCA Healthcare Kansas City/Centerpoint Medical Center, Independence, MO. Electronic address: shahzaib.maqbool@hcamid…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Acute myeloid leukemia (AML) is associated with high early mortality, especially among older adults and those with limited access to care. This study utilizes a national cancer registry to identify demographic and disease-related predictors of early death in AML patients. METHODS: A retrospective cohort analysis was conducted using data from the Surveillance, Epidemiology, and End Results 8 database (November 2024 submission) covering cases diagnosed between 1975 and 2022. Patients with a diagnosis of non-M3 AML, defined by ICD-O-3 histology codes were included. Two primary endpoints were evaluated: early mortality within one month of diagnosis (EM1) and within 2 months of diagnosis (EM2). Binary logistic regression was performed to identify predictors of early mortality, and odds ratios (ORs) with 95% confidence intervals (CIs) were reported. RESULTS: A total of 37,835 patients with non-M3 AML were included (median age 70 years), with early mortality rates of 33.4% at 1 month (EM1) and 39.7% at 2 months (EM2). Early mortality increased markedly with age, reaching 52.8% (EM1) and 62.3% (EM2) in patients > 75 years (P < .001). Receipt of chemotherapy significantly reduced early mortality, with lower EM1 (20.6% vs. 61.2%) and reduced adjusted odds for both EM1 (OR 0.19; 95% CI, 0.18-0.20) and EM2 (OR 0.12; 95% CI, 0.12-0.13) (P < .001). Across diagnostic eras, outcomes improved progressively from the chemotherapy era (1975-2005) to the HMA era (2006-2017) and venetoclax era (2018-2022), with EM1 declining from 37.1% to 30.7% to 29.1% and EM2 from 43.9% to 36.8% to 34.9% (P < .001). Sociodemographic factors were significant in univariate analyses but not after adjustment. CONCLUSION: Early mortality in non-M3 AML remains high and is strongly influenced by age, chemotherapy receipt, and AML subtype. Improving timely treatment access and supportive care for high-risk patients may substantially reduce early deaths.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, HCA Healthcare Kansas City/Centerpoint Medical Center, Independence, MO. Electronic address: shahzaib.maqbool@hcamidwest.com.
- Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
- Department of Internal Medicine, The University of Arizona, Tucson, AZ.
- Department of Internal Medicine, Multan Medical and Dental College, Multan, Pakistan.
- Division of Haematology and Oncology, Memorial Cancer Institute, Hollywood, FL.
- Department of Internal Medicine, NYC H+H/Woodhull, New York City, NY.
Zitieren
APA
Maqbool, S., Rehman, M. E. U., Iftikhar, A., Rehman, A., Ali, M., Khan, A., Khan, I., Ibrahim, M., & Anwer, F. (2026). Predictors of Early Mortality in Acute Myeloid Leukemia: A Population Based Analysis Using SEER Data. Clinical Lymphoma Myeloma and Leukemia, 26(6), 377-387. https://doi.org/10.1016/j.clml.2026.04.005
Vancouver
Maqbool S, Rehman MEU, Iftikhar A, Rehman A, Ali M, Khan A, et al. Predictors of Early Mortality in Acute Myeloid Leukemia: A Population Based Analysis Using SEER Data. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):377-387. doi:10.1016/j.clml.2026.04.005
BibTeX
@article{Maqbool2026,
author = {Maqbool, Shahzaib and Rehman, Mohammad Ebad Ur and Iftikhar, Ahmad and Rehman, Abdur and Ali, Mouzma and Khan, Abat and Khan, Imran and Ibrahim, Muhammad and Anwer, Faiz},
title = {Predictors of Early Mortality in Acute Myeloid Leukemia: A Population Based Analysis Using SEER Data},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {6},
pages = {377--387},
doi = {10.1016/j.clml.2026.04.005}
}
EUVIMED